LB-100

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) received an extension from Nasdaq to meet the minimum stockholders’ equity requirement by February 18, 2025. The company plans to regain compliance through registered equity offerings, aiming to raise up to $4 million. Failure to meet the requirement could result in delisting, but Lixte has the option to appeal. Recent developments include changes in director compensation policy and a clinical trial agreement with the Netherlands Cancer Institute for their cancer drug, LB-100.

Lixte Biotechnology Holdings, Inc. received a Nasdaq extension until February 18, 2025, to meet the $2.5M equity requirement, risking delisting otherwise. It plans equity offerings to raise capital. Recent changes include director compensation to equity-based and a clinical trial agreement for cancer drug LB-100 with the Netherlands Cancer Institute.

LIXTE Biotechnology Holdings, Inc. develops PP2A inhibitors, notably LB-100, enhancing chemotherapy and immunotherapy efficacy. LB-100 promotes neoantigens, cytokines, T-cell proliferation, and disrupts cancer DNA repair, improving treatment outcomes. The company conducts clinical trials for solid tumors, with a unique approach and comprehensive patents.

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) received a Nasdaq non-compliance notice for falling below the $2.5M stockholders' equity requirement. It has 45 days to submit a compliance plan, with a possible 180-day extension. The company is exploring options to regain compliance, while its shares continue trading. Recent changes include a shift to equity-based director compensation and a clinical trial agreement with the Netherlands Cancer Institute for cancer drug LB-100.

A new approach to cancer therapy involves stressing tumor cells with an activator, LB-100, then eliminating them with a WEE1 inhibitor, adavosertib. This 'paradoxical intervention' worked well in mice and is set for a phase 1b clinical trial for advanced colorectal cancer.

Lixte Biotechnology Holdings, Inc. partners with the Netherlands Cancer Institute for a clinical trial of LB-100 combined with atezolizumab for metastatic colon cancer, starting by June 30, 2024. Roche funds the trial and provides atezolizumab, while Lixte supplies LB-100. The trial aims to enhance immune response against cancer, involving up to 37 patients over 24 months.

LIXTE Biotechnology Holdings, Inc. signed an exclusive patent license agreement with NIH's NINDS and NCI, focusing on combining LIXTE’s LB-100 with cancer immunotherapies. This collaboration aims to develop novel combination therapies, enhancing cancer treatment efficacy. LIXTE is conducting clinical trials to assess LB-100's potential in improving chemotherapy and immunotherapy outcomes.

Lixte Biotechnology Holdings, Inc. is offering 180,000 shares of Common Stock at $6.00 per share and Pre-Funded Warrants to purchase up to 403,334 shares at $5.9999 per warrant. The warrants are immediately exercisable at $0.0001 per share. Concurrently, in a private placement, the company is selling Common Warrants to purchase up to 583,334 shares at $6.00 per share, exercisable for five years. The offering aims to raise approximately $3,290,003 for working capital and clinical development of LB-100, a protein phosphatase inhibitor with potential in cancer treatment. The company's stock is listed on Nasdaq under 'LIXT'.

LIXTE Biotechnology Holdings, Inc. announced a securities purchase agreement with a health-care focused institutional investor for 583,334 shares at $6.00 each, including warrants, expecting $3,500,000 gross proceeds. The offering, managed by A.G.P./Alliance Global Partners, is set to close around July 20, 2023, under SEC regulations.

LIXTE Biotechnology Holdings, Inc. announced a $3.5 million registered direct offering and private placement, selling 583,334 shares at $6.00 each, with warrants for an equal number of shares. The offering, managed by A.G.P./Alliance Global Partners, is expected to close around July 20, 2023, aiming to fund cancer therapy development.